Clover Biopharmaceuticals, Ltd. (2197.HK)

0.370 +0.025 (+7.25%) At close: 04:08PM HKT

Clover Biopharmaceuticals, Ltd.

Park Place
49th Floor 1598-1601 West Nanjing Road Jing'an District
Shanghai
China
86 40 0883 3405
https://www.cloverbiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 387

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Peng Liang Ph.D.	Founder, Chief Scientific Officer & Chairman of the Board	4.95M	N/A	1961
Mr. Joshua G. Liang	CEO & Executive Director	8.79M	N/A	1993
Ms. Aileen Wang	Chief Financial Officer	N/A	N/A	1974
Dr. Yang Li Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Ms. Lily Yang	Chief People Officer	N/A	N/A	N/A
Ms. Htay Htay Han MBBS	Chief Medical Officer of Vaccine	N/A	N/A	1969
Dr. Berry Michael Ph.D.	Chief Technical Operation Officer	N/A	N/A	1966
Ms. Abigail Bracha Ph.D.	Senior Vice President of Corporate Strategy & Business Development	N/A	N/A	N/A
Ms. Tracy Wang	Senior Vice President of Head of Regulatory Affairs, China	N/A	N/A	N/A
Dr. Nicholas Jackson M.Sc., Ph.D.	President of Global Research & Development	N/A	N/A	1971

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of vaccines and biologic therapeutic candidates. The company develops SCB-2019 (CpG 1018/Alum), an adjuvanted protein-based COVID-19 vaccine candidate; AdimFlu-S (QIS), a quadrivalent vaccine for the treatment of influenza; SCB-2020S (CAS-1) and Multivalent SARS-CoV-2, a COVID-19 vaccine candidate; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-219M, a human thrombopoietin receptor agonist (TPO-RA), which is in Phase 1 trial for the treatment of chemotherapy-induced thrombocytopenia; and SCB-1001, a rabies vaccine candidate. It develops its vaccines through Trimer-Tag technology platform. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.

Corporate governance

Clover Biopharmaceuticals, Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.